Sware Raises $6M to Accelerate Life Sciences Innovation by Automating FDA-Mandated Software Validation
Summary
First Analysis, LRVHealth and New Stack Ventures Fund Series B to Erase Validation Debt and Empower Fast, Efficient and Safe Life Sciences InnovationBOSTON, June 6, 2024-- Sware, provider of the most complete software validation solution for innovative life sciences companies, today announced that it raised $6 million in Series B funding, bringing its total raised since inception to $26 million. Regulatory bodies around the globe, including the FDA, require companies to validate computer systems used for development and manufacturing to ensure data integrity, security, and reliability. They are highly agile, committed and most importantly flexible in providing solutions meeting our immediate and long-term requirements, said Alvin Coleman, vice president of information technology at G1 Therapeutics. As life sciences companies rely on more advanced technology to speed innovation, software quality assurance is a critical component to meeting the highest safety standards, said Matt Nicklin, managing director at First Analysis. Were investing in Sware because its proven technology can help companies escape the growing challenges of validation debt and more importantly, empower them to bring new innovations to market more quickly, efficiently and safely.